Author Archives: Farrah Dean

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

Philadelphia & Vancouver, British Columbia – September 12, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Therapeutics Announces $8.5 Million Offering Priced At-the-Market Under Nasdaq Rules

Philadelphia & Vancouver, British Columbia – September 11, 2024 – BriaCell Therapeutics Corp. (Nasdaq: BCTX, ...

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

• Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in ...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

• BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with ...

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA, PA and VANCOUVER, British Columbia, September 9, 2024— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director

BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...

BriaCell Announces Investor and Media Outreach Programs

BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) ...

BriaCell Announces Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Million

BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination ...

BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021

• Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in ...